|Company name||Applied Therapeutics, Inc.|
NEW YORK, September 1, 2020 – Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Applied Therapeutics, Inc. (NASDAQ: APLT) on behalf of Applied Therapeutics stockholders. Our investigation concerns whether Applied Therapeutics has violated the federal securities laws and/or engaged in other unlawful business practices.
On or around May 13, 2019, Applied Therapeutics conducted its initial public offering (“IPO”), issuing 4 million shares of common stock priced at $10.00 per share.
On August 17, 2020, Applied Therapeutics disclosed that the U.S. Food and Drug Administration (“FDA”) has placed a partial clinical hold on the Company’s ACTION-Kids study evaluating the Company’s AT-007 product for the treatment of galactosemia. The FDA cited the need for additional technical information related to ensuring that every participant in the study has access to the drug’s benefits.
On this news, Applied Therapeutics’ stock price fell $3.53 per share, or 12.07%, to close at $25.71 per share on August 17, 2020.
If you purchased or otherwise acquired Applied Therapeutics shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at email@example.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.